ALSO NOTED: Adolor to give back pain patch; Dynavax pursues universal flu vaccine; Charles River buys Northwest Kinetics; and m

> Adolor has decided to stop its work on a pain patch licensed three years ago and will hand it back to EpiCept. Adolor says it wants to devote its resources to other development projects. Report

> The San Jose Mercury News profiles Dynavax's work in developing a universal flu vaccine. Article

> Charles River Laboratories has acquired Northwest Kinetics, a 150-bed facility engaged in branded drug studies, for $29.5 million. Report

> Regeneron Pharmaceuticals' IL-1 Trap hit its primary endpoints in a Phase III trial for CIAS1-related autoinflammatory periodic syndromes, or CAPS Regeneron says its will ask the FDA for approval in the second quarter of next year. Report

> The European Commission has granted CytRx's ALS drug arimoclomol orphan drug status. Release

> Sigma Pharmaceuticals has increased its bid for Australian Pharmaceutical Industries. Report

> Human Genome Sciences is touting positive data from a mid-stage trial of its hepatitis drug Albuferon with ribavarin. Report

And Finally… Harvard biologist Marc D. Hauser believes that evolution has programmed our essential views of morality into our neural circuits. Article